$0.04
+0.00%Price chart
Aug 17Aug 24Aug 28Sep 10Sep 22Sep 30Oct 8Oct 28
Key dataOct 28, 2026
Open$0.04
From 52W high−88.51%
Volume138.00
Market cap$1.08M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 28, 2026
Open
$0.04
From 52W high
−88.51%
Volume
138.00
Market cap
$1.08M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.0x
P/E (TTM)
—
RSI (14)
46.4
MomentumView details →
1D Return
+0.00%
YTD Return
+14.29%
SummaryUpdated Jun 1, 2026
Liminatus Pharma, Inc. (NASDAQ:LIMNW) is a clinical-stage immuno-oncology biotechnology company founded and based in La Palma, California. The company went public in April 2025 and focuses on developing novel cancer therapies that harness the body's immune system to fight cancer. As a pre-revenue biotechnology company, Liminatus is in the early stages of drug development, working to advance its therapeutic candidates through clinical trials with the ultimate goal of bringing new cancer treatments to market.
Similar companies
Latest newsMore news →
Liminatus Pharma, Inc. agreed to issue 260,001 common shares to a non-U.S. investor in a private placement for gross proceeds of $650,002.50.20h agoLiminatus Pharma regained compliance with Nasdaq's $1 minimum bid price requirement after effecting a 1-for-50 reverse stock split on August 20, 2026.36d ago